Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06

Executive Summary

GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York

You may also be interested in...



Tykerb Effective In Herceptin Failures; CNS Relapse Rate, CV Safety Touted

GlaxoSmithKline's Tykerb (lapatinib) should replace Genentech's Herceptin (trastuzumab) as the standard of care for trastuzumab-refractory breast cancer patients, GSK Senior VP-Oncology Medicine Development Center Paolo Paoletti said June 3

Tykerb Effective In Herceptin Failures; CNS Relapse Rate, CV Safety Touted

GlaxoSmithKline's Tykerb (lapatinib) should replace Genentech's Herceptin (trastuzumab) as the standard of care for trastuzumab-refractory breast cancer patients, GSK Senior VP-Oncology Medicine Development Center Paolo Paoletti said June 3

Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers

Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment

Related Content

Topics

UsernamePublicRestriction

Register

PS046621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel